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Hantavirus pulmonary syndrome (HPS) is a severe 
respiratory illness identiﬁ  ed in 1993. Since its identiﬁ  cation, 
the Centers for Disease Control and Prevention has 
obtained standardized information about and maintained a 
registry of all laboratory-conﬁ  rmed HPS cases in the United 
States. During 1993–2009, a total of 510 HPS cases were 
identiﬁ  ed. Case counts have varied from 11 to 48 per year 
(case-fatality rate 35%). However, there were no trends 
suggesting increasing or decreasing case counts or fatality 
rates. Although cases were reported in 30 states, most 
cases occurred in the western half of the country; annual 
case counts varied most in the southwestern United States. 
Increased hematocrits, leukocyte counts, and creatinine 
levels were more common in HPS case-patients who died. 
HPS is a severe disease with a high case-fatality rate, and 
cases continue to occur. The greatest potential for high 
annual HPS incidence exists in the southwestern United 
States.
I
n May 1993, a series of cases of an acute illness 
associated with rapid development of respiratory failure 
were noted in the Four Corners region of the United States. 
Surveillance initiated in the area identiﬁ   ed 24 cases of 
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compatible illness that had occurred in New Mexico, 
Arizona, Colorado, and Utah since December 1992; the 
case-fatality rate was 50%. Preliminary serologic data for 
case-patients suggested infection with an unknown virus 
in the family Bunyaviridae and genus Hantavirus (1). This 
observation was surprising, given that hantaviruses had 
not been associated with any human diseases in North or 
South America at that time, and the only known clinical 
syndrome associated with hantaviruses, hemorrhagic 
fever with renal syndrome, did not have a predominantly 
respiratory involvement. However, nucleic acid sequence 
from a novel hantavirus was rapidly identiﬁ  ed in tissue 
samples of multiple patients, and similarly from deer mice 
(Peromyscus maniculatus) trapped near the residence of 
cases, implicating a novel hantavirus as the cause of the 
disease (2). Additional serologic and molecular data from 
case-patients and results of trapping studies in the Four 
Corners region supported these conclusions (3,4).
Since its identiﬁ   cation in 1993, hantavirus 
cardiopulmonary syndrome (HPS) and numerous New 
World hantavirus species have been described across a wide 
geographic range of North, Central, and South America (5). 
In the United States, most HPS cases are likely caused by 
Sin Nombre virus (6), the virus responsible for the initially 
identiﬁ  ed HPS cases. Other HPS-associated viruses include 
New York and Monongahela viruses (mice of the genus 
Peromyscus are reservoirs), associated with HPS in the 
eastern United States (7–9), Bayou virus, found in the 
southeastern United States (Oligoryzomys palustris rice 
rats are reservoirs) (10–12), and Black Creek Canal virus 
(Sigmodon hispidus cotton rats are reservoirs), which was 
associated with 1 case of HPS in Florida (13,14).
Hantaviruses are believed to be transmitted by 
inhalation of rodent secretions and excreta, or possibly 
through direct contact with an infected rodent. Although 
clusters of human cases have been identiﬁ   ed in the 
United States, no evidence exists of human-to-human or 
nosocomial transmission of hantaviruses in North America 
(15,16) Infrequent but clear instances of human-to-human 
transmission of Andes virus in Argentina and Chile have 
been documented (17–19).
The incubation period of HPS is believed to range 
from 1 to 5 weeks (20). HPS typically begins with a 
prodromal syndrome, and common symptoms include 
fever, myalgias, headache, and nausea/vomiting (21,22). 
After the prodrome, the hallmark of HPS is rapid onset 
of a severe pulmonary illness, often involving hypoxia, 
pulmonary edema, and myocardial depression (22–25). 
Death typically occurs rapidly after hospitalization (21) and 
often as the result of cardiogenic shock (25). In this report, 
we evaluate the epidemiologic and clinical characteristics 
of all known laboratory-conﬁ  rmed cases of HPS in the 
United States during 1993–2009.
Materials and Methods
After identiﬁ  cation of HPS in 1993, the Viral Special 
Pathogens Branch at the Centers for Disease Control and 
Prevention (Atlanta, GA, USA) developed and maintained 
a registry of conﬁ  rmed HPS cases in the United States. A 
clinically conﬁ  rmed case of HPS is deﬁ  ned as 1) a febrile 
illness characterized by bilateral diffuse interstitial edema 
that may radiographically resemble acute respiratory 
distress syndrome (ARDS), with respiratory compromise 
requiring supplemental oxygen developing <72 hours 
after hospitalization, and occurring in a previously healthy 
person, or an unexplained respiratory illness resulting 
in death, with an autopsy examination demonstrating 
pulmonary noncardiogenic edema without an identiﬁ  able 
cause; and 2) laboratory evidence of hantavirus infection 
by detection of hantavirus-speciﬁ  c immunoglobulin M or 
increasing titers of hantavirus-speciﬁ  c immunoglobulin G, 
detection of hantavirus-speciﬁ  c RNA sequence by PCR in 
clinical specimens, or detection of hantavirus antigen by 
immunohistochemical analysis (26).
Information for the registry, including demographic, 
geographic, outcome, and (if possible) basic clinical data, 
is obtained by using a case-report form. Although many 
laboratory diagnoses are not made at the Centers for 
Disease Control and Prevention, case-report forms were 
reviewed to verify hantavirus laboratory diagnostics. 
Additionally, since 1995, HPS has been a nationally 
reportable disease in the United States; thus, parallel 
surveillance for HPS is conducted through the National 
Notiﬁ  able Diseases Surveillance System (26). To ensure 
completeness of the registry, we attempted to acquire case-
report forms for all HPS cases reported to the National 
Notiﬁ  able Diseases Surveillance System. For all cases, we 
attempted to acquire qualitative data (yes or no) regarding 
certain clinical signs and symptoms, and laboratory values 
(fever, thrombocytopenia, increased hematocrit, increased 
creatinine levels, leukocyte counts, chest radiograph 
showing unexplained bilateral inﬁ  ltrates or suggestive of 
ARDS, requirement of supplemental oxygen, and whether 
the patient was intubated). For a small number of patients 
for whom incomplete qualitative data were available, but 
for whom laboratory values were available, we assigned 
qualitative values on the basis of described clinical cutoff 
values (24).
Results
Number of HPS Cases and Demographics
During 1993–2009, we identiﬁ   ed 510 laboratory-
conﬁ  rmed cases of HPS in the United States; 31 cases that 
occurred before 1993 had been retrospectively identiﬁ  ed 
(27–29). HPS is primarily a disease of adults; most cases 
were in persons 20–50 years of age (mean age 38 years) 
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(Table 1); 7% of cases occurred in children <16 years of 
age. Among HPS cases, 64% occurred in male patients. 
Most cases occurred in white (78%) or American Indian/
Native American (20%) persons, and 21% of case-patients 
reported their ethnicity as Hispanic.
Temporal and Geographic Characteristics of Cases
The largest annual number of HPS cases registered (n = 
48) occurred in 1993 during the initial investigation. Since 
that time, annual case counts have varied considerably 
from year to year (Figure 1); counts have ranged from 11 
to 45 cases/year (mean 30 cases/year). No signiﬁ  cant trend 
was observed in increasing or decreasing case counts from 
after 1993 (p = 0.400, by general linear model). From a 
population perspective, HPS is rare in the United States; the 
annual incidence has ranged from 0.04 to 0.19 cases/million 
persons on the basis of a US Census Bureau estimate of 
the US population on July 1 of each respective year (www.
census.gov). HPS displayed a strong seasonal distribution; 
the maximum number of cases occurred in May, June, and 
July, and the minimum occurred in December, January, and 
February (Figure 2).
We identiﬁ   ed the probable geographic location of 
rodent exposure (at least to the state level) for 471 cases. 
Probable exposures occurred in 30 US states; most 
cases occurred in the western United States To examine 
trends in HPS occurrence, we grouped states into 4 
regions on the basis of geography and hantavirus species 
present: Southwest (Arizona, California, Colorado, New 
Mexico, Nevada, Utah); Northwest (Idaho, Montana, 
Oregon, Washington, and Wyoming); Midwest (Illinois, 
Indiana, Iowa, Kansas, Louisiana, Minnesota, North 
Dakota, Nebraska, Oklahoma, South Dakota, Texas, and 
Wisconsin); and East (Florida, Maryland, North Carolina, 
New York, Pennsylvania, Virginia, and West Virginia) 
(Table 2).
We assessed temporal trends in HPS for each of these 
regions (with the exception of the East because there were 
only 12 cases) (Figure 3, panel A). Overall case counts were 
relatively stable across the 17-year period in the Northwest 
(mean ± SD 5.9 ± 2.1 cases/year) and Midwest (mean ± 
SD 4.9 ± 2.8 cases/year). In contrast, case counts in the 
Southwest tended to ﬂ  uctuate to a higher degree (mean ± 
SD 16.1 ± 9.8 cases/year). Overall variance in annual case 
counts was signiﬁ  cantly higher in the Southwest than in the 
Northwest (F-statistic p<0.001) or the Midwest (F-statistic 
p<0.001). When combined with annual HPS case counts 
for the entire United States, peaks in HPS case counts in 
the Southwest corresponded directly with peaks for the 
entire country. This ﬁ  nding, in conjunction with stable case 
counts in the Northwest and Midwest, demonstrates that 
annual variability in HPS in the United States is primarily 
driven by ﬂ   uctuations in number of HPS cases in the 
southwestern United States.
We assessed seasonality of HPS by geographic region 
(Figure 3, panel B). Similar to aggregate trends for the 
entire United States, HPS displayed a clear seasonal trend 
in the Midwest, Northwest, and Southwest. In contrast 
to the Midwest and Northwest, in which the highest 
proportion of cases occurred in May and decreased in the 
summer months, HPS cases peaked 2 months later (in July) 
in the Southwest.
Clinical Characteristics and Case-Fatality Rates
The overall case-fatality rate was 35%. Deaths 
varied noticeably from year to year (Figure 1); however, 
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Table 1. Demographic characteristics of HPS case-patients, 
United States, 1993–2009* 
Characteristic 
No. (%) 
cases  
Outcome 
CFR, %  p value† 
Age, y, n = 508      0.992 
 <10  5  (1)  20   
 10–19  56  (11)  36   
 20–29  116  (23)  36   
 30–39  105  (21)  37   
 40–49  101  (20)  33   
 50–59  69  (14)  35   
 60–69  48  (9)  33   
 > 70 8  (2)  38   
Sex, n = 510      0.180 
 M  324  (64)  33   
 F  186  (36)  39   
Race, n = 492      0.284 
 White  383  (78)  33   
  American Indian or 
 Native  American 
96 (20)  43   
 Black  8  (2)  38   
  Asian or Pacific Islander  5 (1)  60   
Ethnicity, n = 393      0.637 
 Non-Hispanic  312  (79)  37   
 Hispanic  81  (21)  40   
*HPS, hantavirus pulmonary syndrome; CFR, case-fatality rate.  
†Ȥ
2 p value for testing the difference in proportion of HPS case-patients 
who died between categories for each demographic characteristic. 
Figure 1. Annual number of cases (bars) of and case-fatality rate 
(line) for hantavirus pulmonary syndrome, United States, 1993–
2009.RESEARCH
no temporal trend in deaths was observed (p = 0.307, by 
Cochran-Armitage trend test). Additionally, case-fatality 
rates were similar across demographic characteristics; no 
differences in case-fatality rates were noted for age groups, 
or by sex, race, or ethnicity (Table 1). Similarly, from a 
geographic standpoint, case-fatality rates did not differ 
between geographic regions (p = 0.773, by χ2 test) (Table 
2). The mean time from onset of symptoms to death was 
6.4 days (median 5 days).
As described (21,22), HPS case-patients had a severe 
respiratory illness (most persons had chest radiographs 
showing unexplained bilateral inﬁ   ltrates or suggestive 
of ARDS, and required supplemental oxygen) and 
thrombocytopenia (Table 3). Other common ﬁ  ndings 
included fever >101°F and increased hematocrits, creatinine 
levels, and leukocyte counts. Increased hematocrits, 
creatinine levels, and leukocyte counts; requirement for 
supplemental oxygen; and necessity for intubation were all 
associated with death of a patient. Additionally, although 
nearly all HPS case-patients had thrombocytopenia, 
platelet counts (lowest measured value during illness) were 
signiﬁ  cantly lower among patients who died than among 
patients who survived (median platelet count in persons 
who died 33,500 cells/mL vs. median in persons who 
survived 51,500 cells/mL; p<0.001 by Wilcoxon rank-sum 
test), for 278 persons for whom data were available.
Discussion
In 1996, Khan et al. published a description of the ﬁ  rst 
100 cases of HPS identiﬁ  ed in the United States (21). Some 
aspects of the epidemiology of HPS in the United States 
have since been discussed in the peer-reviewed literature. 
However, no studies have provided a comprehensive 
evaluation of the epidemiology of HPS in the United 
States. By maintaining a registry and obtaining information 
in standardized manner, we were able to evaluate the 
epidemiologic characteristics of HPS in >500 cases over 
17 years of data collection. Although HPS is a nationally 
reportable disease in the United States, maintenance of 
our registry has enabled us to obtain more detailed and 
standardized information on HPS than otherwise possible 
through other national surveillance mechanisms.
HPS is often characterized as an emerging infectious 
disease. The discovery of a novel clinical syndrome 
and associated virus might constitute emergence from 
a public health perspective. However, several lines of 
evidence indicate the epidemiology of HPS constitutes 
that of an endemic or sporadic disease. First, although 
overall numbers clearly vary from year to year, our data 
demonstrate continual occurrence of HPS since 1993 
without a trend toward an increasing or decreasing number 
of cases. Additionally, HPS cases before 1993 in the 
United States (27–29), possibly as far back as 1959 (30), 
and rodents infected with hantaviruses (6,31) have been 
identiﬁ   ed retrospectively. Similarly, the evolutionary 
history of hantavirus species in the United States appears to 
have been closely linked with that of their primary rodent 
host species and to persist over time among these host 
species (32), consistent with the notion that hantaviruses are 
not newly emergent in the United States. Finally, HPS and 
wide distribution of associated hantavirus species across 
most of the New World do not support recent emergence of 
a novel pathogenic virus.
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Fig    ure 2. Cumulative number of hantavirus pulmonary syndrome 
cases by month of onset, United States, 1993–2009. 
Table 2. HPS case-patients by geographic region, United States, 1993–2009* 
Region States† 
Hantavirus species present in 
region 
No. case-patients who died/ 
total no. case-patients  
(CFR, %)‡ 
Southwest  Arizona, California, Colorado, New Mexico, 
Nevada, Utah 
Sin Nombre virus  92/273 (34) 
Northwest  Idaho, Montana, Oregon, Washington, Wyoming  Sin Nombre virus  35/101 (35) 
Midwest  Illinois, Indiana, Iowa, Kansas, Louisiana, 
Minnesota, North Dakota, Nebraska, Oklahoma, 
South Dakota, Texas, Wisconsin 
Sin Nombre virus, Bayou virus  33/84 (39) 
East  Florida, Maryland, North Carolina, New York, 
Pennsylvania, Virginia, West Virginia 
New York virus, Monongahela 
virus, Black Creek Canal virus 
5/12 (43) 
*HPS, hantavirus pulmonary syndrome; CFR, case-fatality rate. 
†Only states with >1 probable rodent exposure–related HPS case are shown. 
‡There were no significant differences in case-fatality rates between geographic regions (p = 0.773 by Ȥ
2 test). Hantavirus Pulmonary Syndrome, USA, 1993–2009
The distribution of rodent reservoirs of pathogenic 
hantaviruses covers the entire mainland United States 
(33). During 1993–2009, HPS cases were associated with 
probable rodent exposures in 30 US states. However, in 
contrast to the wide distribution of rodent reservoirs, HPS 
is clearly more common in the western United States; only 
a small proportion (<3%) of cases are associated with 
exposures in the eastern United States.  Although the virus 
species responsible for HPS is not typically assessed in 
diagnostic testing, it is likely that most cases of HPS in the 
United States are caused by Sin Nombre virus because of 
the western distribution of the reservoir host of this virus, 
the deer mouse, in comparison with reservoir hosts of other 
pathogenic hantavirus species, which are found primarily 
in the central and eastern United States.
Our examination of the epidemiology of HPS on the 
basis of geographic region has obvious limitations. For 
instance, state boundaries do not necessarily represent 
boundaries of ecosystems or distribution of reservoirs of 
different pathogenic hantavirus species. We noted major 
conclusions from this approach. First, we examined the 
hypothesis that hantavirus species may differ in their 
pathogenic potential. Although the overall number of HPS 
cases in the eastern United States was small (n = 12) and 
infections were potentially caused by multiple hantavirus 
species in the East and Midwest regions, our data do not 
suggest a difference in pathogenicity between hantavirus 
species endemic to the United States. Furthermore, 
systematic viral genotyping is needed to conclusively 
address the hypothesis that hantaviruses in the United 
States may differ in their pathogenic potential in humans. 
Second, annual numbers of HPS cases in the Northwest 
and Midwest were relatively consistent, whereas annual 
HPS case counts in the Southwest were signiﬁ  cantly 
more variable, and peak years of HPS in the Southwest 
corresponded with high overall case-count years in the 
United States. These ﬁ  ndings suggest greater potential for 
increases in HPS in the southwestern United States than in 
other regions of the country.
The HPS case-fatality rate in the United States was 35% 
during 1993–2009. No antiviral treatment is available for 
HPS, and we did not observe a trend in the case-fatality rate 
for HPS over time. No demographic factors were associated 
with deaths caused by HPS outcomes. The apparent rarity of 
HPS in younger persons is notable. However, similar case-
fatality rates for HPS across age groups and results of case 
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Figure 3. Annual number of cases of hantavirus pulmonary syndrome (HPS) (A) and percentage of cases by month of onset (B) by 
geographic region of probable HPS exposure, United States, 1993–2009.
Table 3. Clinical characteristics of HPS case-patients, United States, 1993–2009*  
Characteristic 
No. patients reporting characteristic/no. patients for whom 
data were available for that characteristic (%) 
p value†  All   Died  Survived 
Fever  356/397 (90)  116/132 (88)  239/264 (91)  0.414 
Thrombocytopenia‡  405/418 (97)  131/134 (98)  273/283 (96)  0.477 
Increased hematocrit‡  261/389 (67)  103/130 (79)  157/258 (61)  <0.001 
Increased creatinine level‡  120/286 (42) 
169/234 (72) 
54/93 (58) 
72/83 (87) 
66/193 (34) 
96/150 (64) 
<0.001 
<0.001  Increased leukocyte count‡ 
Chest radiograph showing unexplained bilateral infiltrates 
or suggestive of ARDS 
Need for supplemental o
390/406 (96)  1   35/141 (96) 255/265 (96)  0.812 
xygen 
Intubation of patient 
390/405 (96) 
265/430 (62) 
134/135 (99) 
129/139 (93) 
255/269 (95) 
135/290 (47) 
0.025 
<0.001 
*HPS, hantavirus pulmonary syndrome; ARDS, acute respiratory distres
c who died and those who survived. 
patients for whom qualitati
s syndrome. 
†By Ȥ
2 test for difference in the proportion of HPS case-patients with a clinical characteristi
‡Based on qualitative data (yes or no) regarding clinical characteristic from case investigation form. For a small number of case- v
incomplete, but for whom laboratory values were available, qualitative values were assigned on the basis of described clinical cutoff values (24). RESEARCH
studies of HPS in children (34,35) indicate that severity of 
HPS is likely similar in adults and younger persons. We 
have limited data about the relationship between concurrent 
conditions and HPS outcome. However, similar case-
fatality rates for HPS across age groups (particularly that 
the case-fatality rate remains similar in older persons) does 
not support the notion that underlying health conditions are 
the primary determinant of disease outcome. The actual 
level of virus exposure at the time of infection may also 
be a major determinant of disease severity. A recent study 
reported smoking as a signiﬁ  cant risk factor for Puumala 
virus (genera Hantavirus) infection in Finland (36). We 
believe this ﬁ  nding warrants a study in the United States to 
determine whether smoking might increase the likelihood 
of development or the overall severity of HPS.
HPS is characterized by the rapid onset of a severe 
respiratory disease. Virtually all patients with laboratory-
conﬁ  rmed HPS in our registry for whom clinical data were 
available required supplemental oxygen (96%) and had a 
chest radiograph showing unexplained bilateral inﬁ  ltrates 
or suggestive of ARDS (96%). Although thrombocytopenia 
is a common symptom of HPS, lowest platelet counts were 
lower in fatal HPS cases. Similarly, increased hematocrits, 
creatinine levels, and leukocyte counts occurred in a higher 
proportion in HPS case-patients who died. Although 
similar clinical ﬁ  ndings have been reported for smaller case 
studies (21–24,37), our data demonstrate the role of these 
factors in predicting the outcome of HPS. We also noted 
similar associations between outcomes in patients who 
died and the requirement for supplementary oxygen and 
intubation. These 2 variables represent clinical procedures 
and thus would be expected to be more common in severe 
HPS cases. Although we do not have any data about the 
proportion of case-patients who received extracorpeal 
membrane oxygenation, some studies suggest that this 
procedure might improve the prognosis for severe HPS 
(38,39).
Because of the centralized and passive nature of 
data collection, our methods have some limitations. 
Data collection was limited to a short, standardized case 
investigation form; thus, we were unable to collect detailed 
clinical information and verify clinical information (such 
as radiographic ﬁ  ndings). In addition, clinical aspects of 
our surveillance data were limited to a small number of 
speciﬁ  c criteria. Other investigators have reported signs, 
symptoms, radiographic characteristics, and pathologic 
features of HPS in greater detail (21–24,40). Studies 
have also demonstrated cardiopulmonary depression, and 
resulting cardiogenic shock, as a major pathologic aspect 
of HPS, particularly in patients who died (25). In addition, 
because of the passive nature of HPS surveillance, we 
may have missed some HPS cases in the United States. 
However, through continued outreach with state health 
departments and the ability to cross-check HPS cases with 
those reported through the National Notiﬁ  able Diseases 
Surveillance System, we have attempted to minimize the 
number of HPS cases that might go unregistered. However, 
frequently updated HPS case counts and geographic data 
are available (www.cdc.gov/hantavirus).
Despite its rarity, HPS continues to occur in the United 
States. With a case-fatality rate of 35%, HPS remains 1 of 
the most severe infectious diseases endemic to the United 
States.
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